Announcements Trials

Browse Landscape

Clinical Trials

1 trials

Recent Start date Enrollment

Unilateral HER2 Positive Breast Cancer × Afatinib × Breast × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 15 Stomach Neoplasms 2 Prostatic Neoplasms 2 Pancreatic Neoplasms 2 Neoplasm Metastasis 2 Multiple Myeloma 2 Lung Neoplasms 2 Hematologic Neoplasms 2 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Unilateral HER2 Positive Breast Cancer 1 Triple Negative Breast Neoplasms 1 Thyroid Neoplasms 1 Thrombocytosis 1 Rectal Neoplasms 1 Primary Myelofibrosis 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Pathologic Complete Response 1 Ovarian Neoplasms 1 Myeloproliferative Disorders 1 Myelodysplastic-Myeloproliferative Diseases 1 Myelodysplastic Syndromes 1 Melanoma 1 Lymphoma, Non-Hodgkin 1 Lymphoma 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia, Myeloid, Chronic-Phase 1 Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1 Leukemia, Myeloid, Acute 1

Interventions

Trastuzumab 1 Paclitaxel 1 Epirubicin 1 Cyclophosphamide 1 Afatinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01594177 2014-03-13

DAFNE

GBG Forschungs GmbH

Phase 2 Completed

Unilateral HER2 Positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡